Historically, basic sepsis research has largely focused on characterizing the inflammatory factors driving disease progression, e.g. IL-1β, TNFα, Toll-like receptor 4, etc., with the assumption that blocking these mechanisms of disease in the clinic with either small molecules or monoclonal antibodies will be sufficient to promote survival. This evidence concerns the gene TLR4 and Sepsis.